Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.57 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851086 | 1.00 | CRHR1 (0.57) | CRHR1SLC6A12EGFRACKR3 | |
| SCHEMBL5438380 | 0.83 | EGFR (0.51) | SLC6A12EGFRACKR3 | |
| SCHEMBL1848822 | 0.80 | NPC1 (0.60) | CRHR1 | |
| SCHEMBL1848823 | 0.80 | NPC1 (0.60) | CRHR1 | |
| SCHEMBL13531209 | 0.79 | EGFR (0.48) | SLC6A12EGFRACKR3 | |
| SCHEMBL3214251 | 0.78 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL3214247 | 0.78 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL1851117 | 0.77 | CRHR1 (0.58) | CRHR1ACKR3 | |
| SCHEMBL1851119 | 0.77 | CRHR1 (0.58) | CRHR1ACKR3 | |
| SCHEMBL5431692 | 0.77 | RAB9A (0.60) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | claimed |
| JP-2011529944-A | — | — | 2011-12-15 | — | — | JP | claimed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | claimed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8614213-B2 | Cyclohexyl amide derivatives and their use as CRF-1 receptor antagonists | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8273900-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110152261-A1 | Organic compounds | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2323970-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015655-A1 | CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035898-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035898-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885SLC6A12 4168/4885EGFR 2122/4885 |
| US-20110152261-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885SLC6A12 3977/4885EGFR 2547/4885 |
| US-20140088105-A1 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885SLC6A12 3724/4885EGFR 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.